Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study

被引:10
作者
Bharathi, D. Vijaya [1 ,2 ]
Naidu, A. [2 ]
Jagadeesh, B. [1 ]
Laxmi, K. N. K. Maha [1 ]
Laxmi, P. Revathi Naga [1 ]
Reddy, Pandu Ranga [1 ]
Mullangi, Ramesh [1 ]
机构
[1] Dr Reddys Labs Ltd, Bioanalyt Lab, Hyderabad 500072, Andhra Pradesh, India
[2] JNTU Coll Engn, Dept Chem, Hyderabad 500072, Andhra Pradesh, India
关键词
zafirlukast; human plasma; validation; LC-MS/MS; pharmacokinetics;
D O I
10.1002/bmc.983
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A highly sensitive and specific LC-MS/MS method has been developed and validated for the estimation of zafirlukast (ZFK) with 500 mu L human plasma using valdecoxib as an internal standard (IS). The API-4000 LC-MS/MS was operated under multiple reaction-monitoring mode using the electrospray ionization technique. The assay procedure involved extraction of ZFK and IS from human plasma with ethyl acetate. The resolution of peaks was achieved with 10 mm ammonium acetate (pH 6.4):acetonitrile (20:80, v/v) on a Hypersil BDS C-18 column. The total chromatographic run time was 2.0 min and the elution of ZFK and IS occurred at approximately 1.11 and 1.58 min, respectively. The MS/MS ion transitions monitored were 574.2 -> 462.1 for ZFK and 313.3 -> 118.1 for IS. The method was proved to be accurate and precise at a linearity range of 0.15-600 ng/mL with a correlation coefficient (r) of >= 0.999. The method was rugged with 0.15 ng/mL as lower limit of quantitation. The intra- and inter-day precision and accuracy values were found to be within the assay variability limits as per the FDA guidelines. The developed assay method was applied to a pharmacokinetic study in human volunteers following oral administration of 20 mg ZFK tablet. Copyright (C) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:645 / 653
页数:9
相关论文
共 10 条
[1]   Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection [J].
Bui, KH ;
Kennedy, CM ;
Azumaya, CT ;
Birmingham, BK .
JOURNAL OF CHROMATOGRAPHY B, 1997, 696 (01) :131-136
[2]   Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluid [J].
Dams, R ;
Huestis, MA ;
Lambert, WE ;
Murphy, CM .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2003, 14 (11) :1290-1294
[3]   Pharmacokinetic profile of zafirlukast [J].
Dekhuijzen, PNR ;
Koopmans, PP .
CLINICAL PHARMACOKINETICS, 2002, 41 (02) :105-114
[4]   Validation of a LC method for the analysis of zafirlukast in a pharmaceutical formulation [J].
Ficarra, R ;
Ficarra, P ;
Tommasini, S ;
Melardi, S ;
Calabrò, ML ;
Furlanetto, S ;
Semreen, M .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 23 (01) :169-174
[5]   Merit functions for complementarity and related problems: A survey [J].
Fischer, A ;
Jiang, H .
COMPUTATIONAL OPTIMIZATION AND APPLICATIONS, 2000, 17 (2-3) :159-182
[6]   The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory [J].
Hubert, P ;
Chiap, P ;
Crommen, J ;
Boulanger, B ;
Chapuzet, E ;
Mercier, N ;
Bervoas-Martin, S ;
Chevalier, P ;
Grandjean, D ;
Lagorce, P ;
Lallier, M ;
Laparra, MC ;
Laurentie, M ;
Nivet, JC .
ANALYTICA CHIMICA ACTA, 1999, 391 (02) :135-148
[7]   Determination of zafirlukast by stability indicating LC and derivative spectrophotometry [J].
Radhakrishna, T ;
Satyanarayana, J ;
Satyanarayana, A .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (03) :695-703
[8]   Optimisation, validation and application of a capillary electrophoretic method for the determination of zafirlukast in pharmaceutical formulations [J].
Suslu, Incilay ;
Demircan, Seyda ;
Altinoz, Sacide ;
Kir, Sedef .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 44 (01) :16-22
[9]  
Süslü I, 2006, J AOAC INT, V89, P1557
[10]  
US DHHS FDA CDER CVM, 2001, GUID IND BIOAN METH